The role of the receptor activator of nuclear factor κB (NF‐κB) ligand (RANKL)—a tumor
necrosis factor (TNF)‐related cytokine—in osteoclast formation has been established …

Identification of receptor activator of nuclear factor-κB (RANK) and RANK-ligand (RANKL)
has provided new insights into the osteoclast differentiation pathway. Osteoclast precursor …

Osteoclasts are bone-resorbing cells that differentiate from macrophage precursors in
response to receptor activator of NF-κB ligand (RANKL). In vitro models of osteoclast …

Expression of RANKL by stromal cells and of RANK and both NF‐κB p50 and p52 by
osteoclast precursors is essential for osteoclast formation. To examine further the role of …

Osteoclasts are bone-resorbing cells that are derived from haemopoietic precursors,
including cells present in peripheral blood. The recent identification of RANKL [receptor …

Receptor activator of NF-κB ligand (RANKL) and interleukin-1 (IL-1) individually plays a
critical role in the differentiation and activation of osteoclasts in bone. In addition, both …

Osteoclasts develop from hematopoietic cells of the monocyte-macrophage lineage. The
coculture system of osteoblasts and hematopoietic cells was devised to examine …

Receptor activator of nuclear factor-κB ligand [RANK ligand (RANK-L)] stimulates mature
osteoclasts to resorb bone, a process associated with NF-κB activation. RANK-L also …

Homeostasis of the skeletal system is maintained by a balance between bone formation and
resorption. The receptor activator of NF-κB ligand (RANKL) induces the differentiation of …

Osteoclasts, the multinucleated giant cells that resorb bone, originate from hemopoietic cells
of the monocyte-macrophage lineage (1, 2). We have developed a mouse bone marrow …